
    
      Study A536-05 is an open-label extension study to evaluate the safety, tolerability, and
      pharmacodynamic effects of up to 24 months of ACE-536 treatment in patients with low or
      intermediate-1 risk myelodysplastic syndromes previously treated with ACE-536 for up to 3
      months in study A536-03 (ClinicalTrials.gov Identifier NCT01749514). The starting dose level
      in study A536-05 will be 1.0 mg/kg by subcutaneous (SC) injection every 3 weeks. Dose
      titration/modification rules will be followed for individual patients and will be based upon
      safety and efficacy data collected during the course of treatment.
    
  